(Q45314355)

English

Inhibition of Signaling by Overexpressed EGFR

An instance of the biological pathway in Homo sapiens with Reactome ID (R-HSA-5638303)

In more languages

Statements

biological pathway

1 reference

8 July 2022

Signaling by Overexpressed Wild-Type EGFR in Cancer

1 reference

13 July 2022

1 reference

8 July 2022

https://identifiers.org/reactome:R-HSA-5638303

1 reference

8 July 2022

Inactivation of over-expressed wild type EGFR by Cetuximab recombinant antibody

1 reference

8 July 2022

Covalent tyrosine kinase inhibitors bind and inhibit wild-type EGF:EGFR dimers

1 reference

8 July 2022

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

8 July 2022

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

1 reference

8 July 2022

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

8 July 2022

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

1 reference

8 July 2022

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

8 July 2022

Identifiers

1 reference

8 July 2022

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45314355&oldid=1676783028"